Mylan cuts 15 pct of workforce at West Virginia plant

April 20 (Reuters) - Generic drugmaker Mylan NV on Friday announced layoffs of about 15 percent of its workforce at a pharmaceutical manufacturing plant in Morgantown, West Virginia.

The company, which had faced intense criticism and political scrutiny over price hikes for its life-saving EpiPen emergency allergy treatment, said the Morgantown plant "needed to be rightsized to be less complex" for continued operations.

The layoffs involved more than 400 employees represented by a United Steel Workers local union, reported WAJR, a Morgantown radio station.

Mylan said the affected employees were primarily in operations. It said it continues to employ about 3,000 people in West Virginia. 

RELATED: Check out LinkedIn's top companies of 2018:

50 PHOTOS
LinkedIn top 50 companies 2018
See Gallery
LinkedIn top 50 companies 2018
#50: Abbott
#49: Tableau Software 
#48: JLL
#47: PepsiCo
#46: Starbucks
#45: Johnson & Johnson 
#44: Box
#43: Twitter
#42: Capital One
#41: ADP
#40: Square Inc. 
#39: National Football League
#38: Kering 
#37: Citadel 
#36: WeWork
#35: Nike 
#34: Accenture
#33: National Basketball Association 
#32: DropBox 
#31: Cisco 
#30: Stryker
#29: Ernst and Young
#28: Morgan Stanley
#27: Live Nation
#26: Boston Consulting Group 
#25: PwC 
#24: Goldman Sachs 
#23: Verizon 
#22: Deloitte
#21: Samsung 
#20: IBM 
#19: LVMH 
#18: J.P. Morgan Chase & Co.
#17: Dell Technologies
#16: Time Warner
#15: Airbnb
#14: Adobe
#13: McKinsey & Company
#12: Uber 
#11: Spotify 
#10: Netflix 
#9: Oracle 
#8: The Walt Disney Company 
#7: Comcast NBCUniversal 
#6: Apple 
#5: Tesla 
#4: Salesforce
#3: Facebook
#2: Alphabet
#1: Amazon 
HIDE CAPTION
SHOW CAPTION
of
SEE ALL
BACK TO SLIDE

 

"We remain committed to a U.S. manufacturing base and plan to continue making the majority of the medicines we supply to the U.S in the U.S.," Mylan said in a statement.

Generic drugmakers have seen profits shrink due to intensifying pricing pressure on the low-cost pharmaceuticals.

Mylan's bottom line has also been hit by its decision to sell a generic EpiPen for about half the price of the branded product in response to public outrage in 2016. Consumers saw the price for a pack of two auto-injectors rise sixfold to $600 in less than a decade, making them unaffordable for a growing number of families.

The Morgantown plant is not involved in EpiPen production. EpiPens are manufactured for Mylan by Pfizer Inc at a plant in St. Louis, which has experienced production problems that have led to shortages in some international markets, including Canada and Britain. (Reporting by Bill Berkrot, Editing by Rosalba O'Brien)

Read Full Story